CS Diagnostics Reports Q3 2025 Revenue of $23,050, Net Income Increase Despite Year-Over-Year Decline

CS Diagnostics Corp. reported its financial results for the third quarter of 2025, revealing total revenues of $23,050 for the three months ending September 30, 2025, compared to $7,964 for the same period in 2024. For the nine-month period, revenues decreased to $94,200 from $106,381 year-over-year, marking an 11% decline attributed to reduced diagnostic service activity and lower one-time licensing income. Despite the revenue drop, the company achieved a net income of $32,081 for the nine months, a significant increase from $13,448 in the prior year, primarily due to a reduction in operating expenses.

Operating expenses for the nine months ended September 30, 2025, decreased to $62,119 from $92,933 in the same period of 2024. This reduction was largely due to lower professional fees following the completion of several one-time legal and consulting engagements in 2024. General and administrative expenses rose slightly to $22,424, reflecting increased compliance costs associated with the company's OTCQB listing status. The company reported total assets of $499,431,013, with intangible assets accounting for approximately $499.4 million, and a modest increase in liabilities to $1,609 from $1,428 at the end of 2024.

CS Diagnostics continues to focus on transitioning from its development stage to operational efficiency, emphasizing cost management and the expansion of its intellectual property portfolio. The company is actively pursuing new service agreements and expanding its diagnostic offerings, which management believes will stabilize and potentially increase revenues in the latter half of 2025. As of September 30, 2025, the company had 137,340,200 shares of common stock issued and outstanding, with an accumulated deficit of $4,735,847.

Looking ahead, CS Diagnostics is committed to executing its growth strategy, which includes expanding diagnostic services in the U.S., Europe, and MENA regions, advancing proprietary technologies, and leveraging intellectual property for recurring revenues. Management anticipates moderate revenue growth and improved cash flow as newly executed licensing agreements begin to yield results. However, the company acknowledges that its ability to continue as a going concern is contingent upon achieving profitability and securing additional financing, raising substantial doubt about its future operations.

In addition to its financial performance, CS Diagnostics is involved in ongoing legal proceedings, including a civil action against a minority shareholder and another against a third party attempting to sell its diagnostic product. The company continues to evaluate strategic financing and partnership opportunities to support its commercialization and regulatory initiatives, although no definitive agreements have been executed as of the filing date.